RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Target: TARDBP
Composite Score: 0.465
Price: $0.46▲77.5%
Citation Quality: Pending
neurodegeneration
Status: proposed
🟢 Parkinson's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
✓ All Quality Gates Passed
Quality Report Card click to collapse
C
Composite: 0.465
Top 80% of 1374 hypotheses
T1 Established
Multi-source converged and validated
T0 Axiom requires manual override only
C+
0.50
Top 77%
C
0.40
Top 82%
A
0.85
Top 20%
D
0.25
Top 94%
C
0.45
Top 89%
D
0.30
Top 89%
D
0.25
Top 96%
B+
0.75
Top 30%
D
0.35
Top 92%
D
0.30
Top 93%
Evidence
3 supporting
|
3 opposing
Citation quality: 100%
Debates
1 session
A+
Avg quality: 0.95
Convergence
1.00
A+
7 related hypothesis share this target
From Analysis:
Protein aggregation cross-seeding across neurodegenerative diseases
What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
Hypotheses from Same Analysis (6)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Transglutaminase-2 Cross-Linking Inhibition Strategy
Score: 0.639 | Target: TGM2
Glycosaminoglycan Template Disruption Approach
Score: 0.597 | Target: HSPG2
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.584 | Target: TREM2
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.551 | Target: G3BP1
HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Score: 0.544 | Target: DNAJB6
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.469 | Target: PHB2
Description
Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
graph TD
A["TDP-43 / TARDBP"] --> B["RNA Processing Functions"]
B --> C["Splicing Regulation"]
B --> D["RNA Transport"]
B --> E["RNA Stability"]
F["Pathological Conditions"] --> G["Cytoplasmic Mislocalization"]
G --> H["Hyperphosphorylation"]
H --> I["TDP-43 Aggregation"]
I --> J["Cross-Seeding with Other Proteins"]
J --> K["ALS/FTD Pathology"]
L["RNA-Binding Competition Therapy"] --> M["Designed RNA Decoys"]
M --> N["Compete for TDP-43 RNA-Binding Domain"]
N --> O["Sequester TDP-43 in Soluble Form"]
O --> P["Prevent Cytoplasmic Aggregation"]
O --> Q["Block Cross-Seeding"]
O --> R["Preserve Some RNA Processing"]
P --> S["Reduced TDP-43 Inclusions"]
Q --> T["Prevented Prion-like Spread"]
R --> U["Maintained Cellular Function"]
S --> V["Neuroprotection in ALS/FTD"]
T --> V
U --> V
style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
style F fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
style L fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations
6 with PMID
Validation: 100%
3 supporting / 3 opposing
✓
For
(3)
(3)
Against
✗
High
Medium
Low
High
Medium
Low
Evidence Matrix
— sortable by strength/year, click Abstract to expand
Evidence Types
MECH 6CLIN 0GENE 0EPID 0
Legacy Card View — expandable citation cards
✓ Supporting Evidence 3
TDP-43 binds tau mRNA and regulates its translation
RNA molecules can template protein aggregation and cross-seeding
Synthetic aptamers successfully modulate TDP-43 RNA interactions
✗ Opposing Evidence 3
TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic
RNA aptamers show poor CNS penetration and rapid degradation
TDP-43 pathology often involves loss rather than gain of RNA binding function
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼
Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration
Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor
Description: DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.Target: DNAJB6 (DnaJ heat shock protein family member B6)
Supporting Evidence: DNAJB6 pote
🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.
Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor
Specific Weaknesses:
- The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
- No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
- The cited PMIDs don't actually support cross-seeding inhibition claims
- DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID
🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼
PRACTICAL FEASIBILITY ASSESSMENT
Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor
Druggability: MODERATE-POOR
- Target Class: Heat shock protein co-chaperone (difficult to drug directly)
- Chemical Matter: Limited. No known direct DNAJB6 activators exist
- Existing Tools:
- HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
- Gene therapy vectors for DNAJB6 overexpression (preclinical only)
- Direct competitors: None targeting DNAJB6 specifically
- Adjacent space: Multiple HSP70/HSP90 programs (Orphazy
⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼
Price History
7d Trend
↔
Stable
7d Momentum
▼ 0.9%
Volatility
Low
0.0136
Events (7d)
6
⚡ Price Movement Log
Recent 15 events
| Event | Price | Change | Source | Time | |
|---|---|---|---|---|---|
| 📄 | New Evidence | $0.412 | ▲ 3.3% | evidence_batch_update | 2026-04-13 02:18 |
| 📄 | New Evidence | $0.399 | ▲ 6.7% | evidence_batch_update | 2026-04-13 02:18 |
| ⚖ | Recalibrated | $0.374 | ▼ 1.5% | 2026-04-10 15:58 | |
| ⚖ | Recalibrated | $0.380 | ▲ 1.8% | 2026-04-10 15:53 | |
| ⚖ | Recalibrated | $0.373 | ▲ 0.3% | 2026-04-08 18:39 | |
| ⚖ | Recalibrated | $0.372 | ▼ 0.9% | 2026-04-04 16:38 | |
| ⚖ | Recalibrated | $0.375 | ▼ 3.9% | 2026-04-04 16:02 | |
| 📄 | New Evidence | $0.391 | ▲ 4.5% | evidence_batch_update | 2026-04-04 09:08 |
| ⚖ | Recalibrated | $0.374 | ▼ 22.4% | 2026-04-03 23:46 | |
| 💬 | Debate Round | $0.482 | ▲ 8.0% | market_dynamics | 2026-04-03 08:45 |
| 📊 | Score Update | $0.446 | ▼ 9.3% | market_dynamics | 2026-04-03 05:54 |
| 📄 | New Evidence | $0.492 | ▲ 51.8% | market_dynamics | 2026-04-03 03:12 |
| 📄 | New Evidence | $0.324 | ▲ 31.3% | market_dynamics | 2026-04-03 00:26 |
| 💬 | Debate Round | $0.247 | ▼ 53.0% | market_dynamics | 2026-04-02 23:50 |
| 📄 | New Evidence | $0.525 | ▼ 9.4% | market_dynamics | 2026-04-02 22:49 |
Clinical Trials (3) Relevance: 24%
0
Active
Active
0
Completed
Completed
1,610
Total Enrolled
Total Enrolled
ENROLLING_BY_INVITATION
·
NCT06875739 · Fondazione Don Carlo Gnocchi Onlus
310 enrolled · 2025-02-14 · → 2026-10-01
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's
Neurodegenerative Disorders Parkinson Disease Alzheimer Disease
RECRUITING
·
NCT06339190 · Monash University
1,000 enrolled · 2021-08-01 · → 2025-12
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level
Neurodegenerative Diseases Dementia
Venepuncture
RECRUITING
·
NCT03865420 · Columbia University
300 enrolled · 2018-09-11 · → 2027-01
This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it pr
ALS
📚 Cited Papers (45)
ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies.
Current opinion in neurobiology (2026) · PMID:41570741
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration.
Nature neuroscience (2022) · PMID:34916658
17 figures
Extended Data Fig. 1
Characterizations of GFP-hTDP-43 expression in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection of AAV9.CAG.hTDP-43.GFP in C5...
pmc_api
Extended Data Fig. 2
Characterizations of motor deficits and neuronal loss in a neonatal TDP-43 mouse model. GFP-hTDP-43 expression was induced via intracerebroventricular injection of AAV9.CAG.hTDP-43...
pmc_api
Characterizing the RNA targets and position-dependent splicing regulation by TDP-43.
Nature neuroscience (2011) · PMID:21358640
4 figures
Figure 1
Comparison of TDP-43 RNA binding in healthy and FTLD-TDP brain (a) To validate specificity of TDP-43 antibody for iCLIP, the 32 P-labelled RNA bound to TDP-43 gel was isolated fr...
pmc_api
Figure 2
TDP-43 binding motif analysis (a) z-scores of penamer occurrence within the 61 nt sequence surrounding all crosslink sites (−30 nt to +30 nt) are shown for healthy and FTLD-TDP br...
pmc_api
Cardiomyocyte-derived calcitonin regulates atrial fibrosis and AF.
Nature reviews. Cardiology (2021) · PMID:33199879
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
The Genetics of TDP-43 Type C Neurodegeneration: A Whole-Genome Sequencing Study and Literature Review.
Neurology. Genetics (2026) · PMID:41883703
1 figure
Figure 1
Imaging and Pathological Data for the TDP-C Cases With Rare Genetic Variants of Interest (A) Neuroimaging for the probable TDP-C case of svPPA with FIG4 variant. These MRI-based ...
pmc_api
Protein transmission in neurodegenerative disease.
Nat Rev Neurol (2020) · PMID:32203399
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
SMS2 deficiency impairs PKCδ-regulated B cell tolerance in the germinal center.
Cell reports (2021) · PMID:34469734
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
TDP-43 Pathology in Alzheimer's Disease.
Mol Neurodegener (2021) · PMID:34930382
4 figures
Fig. 1
Protein structure of transactive response DNA binding protein of 43 kDa (TDP-43). TDP-43 is a 414 amino acid protein with a nuclear localization sequence (NLS) followed by two RNA ...
pmc_api
Fig. 2
Representative images of TDP-43 pathology subtypes in FTLD-TDP brains. (A) Immunohistochemistry with an anti-phosphorylated-TDP-43 antibody (pSer409/pSer410) shows numerous neurona...
pmc_api
Amyotrophic lateral sclerosis.
Orphanet journal of rare diseases (2009) · PMID:19192301
1 figure
Figures
Figures available at source paper (no open-access XML found).
deep_link
Magnetic control of tokamak plasmas through deep reinforcement learning.
Nature (2022) · PMID:35173339
9 figures
Fig. 1
Representation of the components of our controller design architecture. a , Depiction of the learning loop. The controller sends voltage commands on the basis of the current plasma...
pmc_api
Fig. 2
Fundamental capability demonstration. Demonstration of plasma current, vertical stability, position and shape control. Top, target shape points with 2 cm radius (blue circles), com...
pmc_api
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS.
Cell (2020) · PMID:33031745
12 figures
Figure 1
No caption available
pmc_api
Figure S1
Elevated NF-κB and Type I IFN Signaling Because of TDP-43 In Vitro , Related to Figure 1 (A) Doxycycline (Dox inducible wild-type (WT) or ALS mutant (Q331K) TDP-43 was stably tra...
pmc_api
Amyotrophic lateral sclerosis.
Orphanet journal of rare diseases (2009) · PMID:19192301
No extracted figures yet
📙 Related Wiki Pages (15)
EED geneANXA11 — Annexin A11 geneAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLM ai_toolALS8 - Amyotrophic Lateral Sclerosis 8 geneTARDBP Mutations in Amyotrophic Lateral Sclerosis diseaseANO8 (Anoctamin 8) geneALS10 - Amyotrophic Lateral Sclerosis 10 (TARDBP) geneFamilial vs Sporadic Neurodegeneration Comparison diseasemitochondrial-dysfunction-neurodegeneration-compar diseaseGene Page: ALS4 (SENATAXIN) geneFTD Dataset Rankings datasetUPenn Observational Research Repository (NCT047153 clinicalNeurodegeneration diseaseAmyotrophic Lateral Sclerosis redirectALS9 - Amyotrophic Lateral Sclerosis 9 gene
📓 Linked Notebooks (4)
📓 SciDEX Analysis: 2026 04 01 Gap 9137255B
Computational notebook for SDA-2026-04-01-gap-9137255b
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Analysis Notebook
Jupyter notebook for analysis SDA-2026-04-01-gap-9137255b: What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
📓 Protein aggregation cross-seeding across neurodegenerative diseases — Rich Analysis
Enhanced notebook with gene expression, pathway enrichment, score heatmaps, and statistical analysis. What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative dise …
📓 Protein aggregation cross-seeding across neurodegenerative diseases
What are the mechanisms underlying protein aggregation cross-seeding across neurodegenerative diseases?
Wiki Pages
EEDgeneANXA11 — Annexin A11geneAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_toolALS8 - Amyotrophic Lateral Sclerosis 8geneTARDBP Mutations in Amyotrophic Lateral SclerosisdiseaseANO8 (Anoctamin 8)geneALS10 - Amyotrophic Lateral Sclerosis 10 (TARDBP)geneFamilial vs Sporadic Neurodegeneration Comparisondiseasemitochondrial-dysfunction-neurodegeneration-compardiseaseGene Page: ALS4 (SENATAXIN)geneFTD Dataset RankingsdatasetUPenn Observational Research Repository (NCT047153clinicalNeurodegenerationdiseaseAmyotrophic Lateral SclerosisredirectALS9 - Amyotrophic Lateral Sclerosis 9gene
Dependency Graph (3 upstream, 0 downstream)
Linked Experiments (7)
TDP-43 mitochondrial invasion and DNA release via mPTPexploratory | tests | 0.90TDP-43 mutant mouse model cGAS/STING pathway analysisvalidation | tests | 0.90TDP-43 mitochondrial invasion and mtDNA release in iPSC motor neuronsexploratory | tests | 0.90cGAS/STING pathway validation in TDP-43 mutant micevalidation | tests | 0.85cGAMP biomarker analysis in ALS patient spinal cord samplesexploratory | tests | 0.80TDP-43 pathology prevalence and distribution in AD casesexploratory | tests | 0.80Cognitive impact of TDP-43 pathology in AD patientsclinical | tests | 0.70
Related Hypotheses
Cross-Seeding Prevention Strategy
Score: 0.689 | neurodegeneration
Glial Neuroinflammatory Amplification by TDP-43 Pathology
Score: 0.680 | neurodegeneration
Glycine-Rich Domain Competitive Inhibition
Score: 0.640 | neurodegeneration
Synaptic RNA Metabolism Dysregulation
Score: 0.620 | neurodegeneration
Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-17, blocking autophagosome-lysosome fusion
Score: 0.600 | neurodegeneration
Estimated Development
Estimated Cost
$0
Timeline
2.0 years
🧪 Falsifiable Predictions (4)
4 total
0 confirmed
0 falsified
If hypothesis is true, intervention competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets
pending
conf: 0.40
Expected outcome: competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets
Falsified by: Intervention fails to competitively bind to TDP-43's RRM domains with greater specificity and affinity than endogenous RNA targets
If hypothesis is true, intervention be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)
pending
conf: 0.40
Expected outcome: be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)
Falsified by: Intervention fails to be engineered to contain optimized UG/GU-rich sequences or novel binding motifs identified through systematic evolution of ligands by exponential enrichment (SELEX)
If hypothesis is true, intervention be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs
pending
conf: 0.40
Expected outcome: be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs
Falsified by: Intervention fails to be designed to specifically target TDP-43's RNA recognition motifs (RRMs), thereby disrupting its aberrant interactions with tau (MAPT) and α-synuclein (SNCA) mRNAs
If hypothesis is true, intervention be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities
pending
conf: 0.40
Expected outcome: be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities
Falsified by: Intervention fails to be designed with specific secondary structures that stabilize TDP-43 in conformations incompatible with cross-seeding activities
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬 TARDBP — PDB 4BS2 Click to expand 3D viewer
Source Analysis
Protein aggregation cross-seeding across neurodegenerative diseases
neurodegeneration | 2026-04-01 | completed
Community Feedback
0
0 upvotes · 0 downvotes
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!